Compare ARWR & MOH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARWR | MOH |
|---|---|---|
| Founded | 2003 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 8.9B |
| IPO Year | 1993 | 2003 |
| Metric | ARWR | MOH |
|---|---|---|
| Price | $67.81 | $193.74 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 13 |
| Target Price | $73.70 | ★ $210.92 |
| AVG Volume (30 Days) | ★ 2.6M | 1.3M |
| Earning Date | 02-05-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 16.24 |
| Revenue | $829,448,000.00 | ★ $42,842,000,000.00 |
| Revenue This Year | N/A | $15.20 |
| Revenue Next Year | N/A | $4.03 |
| P/E Ratio | ★ N/A | $11.78 |
| Revenue Growth | ★ 23258.15 | 14.11 |
| 52 Week Low | $9.57 | $133.40 |
| 52 Week High | $76.76 | $359.97 |
| Indicator | ARWR | MOH |
|---|---|---|
| Relative Strength Index (RSI) | 57.08 | 71.49 |
| Support Level | $61.65 | $176.24 |
| Resistance Level | $68.24 | $195.01 |
| Average True Range (ATR) | 3.79 | 7.38 |
| MACD | -0.69 | 0.94 |
| Stochastic Oscillator | 45.29 | 93.24 |
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
Molina provides medical insurance plans through Medicaid, the individual exchanges, and Medicare. It manages health benefit risks for more than 5 million people, with more than 85% of those members coming through contracts with state governments for their Medicaid programs. Medicaid contracts in just four states—California, New York, Texas, and Washington—account for over half of its enrollees.